Operator

Welcome to the Implantica Q1 2026 report presentation. [Operator Instructions] Now I will hand the conference over to the speakers, CEO, Peter Forsell; CFO, Andreas Öhrnberg; and Chief Corporate Affairs Officer, Nicole Pehrsson. Please go ahead.

Peter Forsell
Founder & CEO

Yes. Welcome, everybody, to Implantica's Q1 2026 report. And I will, as usual, start with a short little introduction that you have maybe heard a few times before, but I will try to do it as quick as possible.

So -- so my name is Peter Forsell, sorry for the delay. And as you know, I'm the founder of this company and also a surgeon and the inventor of the products we have. And I've invested lots of money in this company, and they are based on my previous business was a gastric band business, who was very successful and later sold to Johnson & Johnson. So our main cornerstone product is RefluxStop, and that's working in the treatment field of 1 billion sufferers, an enormous field. It's only obesity who can match these kind of levels of disease.

So RefluxStop, you see on the picture here with a nice tool that we supply to the hospitals to place it. On the next slide, you see a closer picture how RefluxStop looks. It's made in 5 pieces. Today, we have 50 hospitals who do the procedure in Europe, and we have done around 1,500 surgeries so far. And existing treatments in the past has always been focusing on that it's the sphincter, the closing muscle between the stomach and esophagus is